Physician profile
Kim Einhorn
NPI 1629284955
$4,005.88
in general payments reported to CMS, 2019-2025
38 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $496 · 2021: $1,076 · 2022: $881 · 2023: $632 · 2024: $229 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.44 | 2019-2024 | |
| Therapeuticsmd, INC. | $382.47 | 2019-2022 | |
| Aspira Women'S Health INC | $265.25 | 2021-2023 | Ova1 |
| Exeltis, USA INC. | $257.67 | 2020-2023 | Slynd |
| Allergan, INC. | $225.60 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $152.56 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.93 | 2019-2023 | |
| Pfizer INC. | $133.51 | 2019-2024 | |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Sumitomo Pharma America, INC. | $111.01 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $108.13 | 2022-2024 | Veozah |
| Coopersurgical, INC. | $95.28 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $91.76 | 2021-2023 | Nexplanon |
| Mylan Pharmaceuticals INC. | $87.19 | 2021-2022 | |
| Myovant Sciences INC. | $84.85 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $82.51 | 2024-2025 | Aptima |
| Evofem Biosciences, INC. | $76.27 | 2021-2024 | |
| Avion Pharmaceuticals | $64.59 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $55.91 | 2019-2023 | Belsomra |
| Lupin INC. | $45.95 | 2019 | |
| Dysis Medical, INC. | $39.68 | 2022 | |
| Urovant Sciences INC | $35.60 | 2022 | |
| Agile Therapeutics, INC. | $34.08 | 2021 | |
| Daiichi Sankyo INC. | $34.01 | 2021-2022 | |
| Davol INC. | $32.76 | 2023 | Arista Ah Flexitip |
| Smith+Nephew, INC. | $29.06 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $27.34 | 2020 | |
| Amgen INC. | $24.15 | 2020 | |
| Renovia INC | $23.65 | 2021 | |
| Covidien LP | $20.61 | 2020 | |
| Scynexis, INC. | $18.24 | 2022 | |
| Millicent US INC | $16.50 | 2019 | |
| Medicem INC. | $16.34 | 2020 | |
| Duchesnay USA Incorporated | $16.06 | 2019 | |
| Minerva Surgical, INC | $15.71 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.90 | 2020 | |
| Mission Pharmacal Company | $12.07 | 2019 | |
| Meditrina | $10.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Einhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.